HLA Loss of Heterozygosity Evaluation
Order Code: 2722 Get Requisition Form
This test is intended for patients with confirmed disease relapse post-hematopoietic cell transplant to evaluate the presence or absence of genomic loss of heterozygosity in the HLA region in malignant cell populations.
Stem Cell Transplantation
Na Heparin Whole Blood or Bone Marrow (Green top)
2-3ml Na Heparin Bone Marrow or 5-10ml Na Heparin Whole Blood (Green top)
Minimum / Pediatric Volume
1ml Na Heparin Bone Marrow or 5ml Na Heparin Whole Blood (Green top)
Additional Sample Information
Test requires fresh blood or bone marrow with malignant cell counts ideally at 5% or greater. Collect in Na Heparin, store and ship ambient same day. Must be received at Hematologics within 72 hours after collection. Indicate on specimen tube and requisition whether sample is whole blood or bone marrow.
- 88184 (first marker)
- 88185 (each addl marker)
Malignant cells are enriched by flow-based cell sorting targeting specific cell surface markers. Genomic DNA from the sorted cells is extracted and analyzed for loss of HLA heterozygosity (LOH) using STR markers and next generation sequencing.
New York State Approval